NovaMed Files Form 10-SB With SEC To Be Fully-Reporting Company

Business Wire, August 4, 1999

MINNEAPOLIS--(BUSINESS WIRE)--Aug. 4, 1999--

NovaMed, Inc. (OTCBB: NVMD) has filed a Form 10-SB with the Securities and Exchange Commission as the initial submission in the process of becoming a fully reporting company pursuant to the Exchange Act of 1934 and recent rulings from the National Association of Securities Dealers (NASD).

Once the Form 10-SB has been accepted for review by the SEC, absent any comment from the SEC as to the adequacy of the submission, the Form 10-SB is declared effective by operation of law within 60 days. When it is declared effective by the SEC, through operation of law or after response to comments, NovaMed, Inc. will be considered a fully reporting company. The company's Form 10-SB will be retrievable at the SEC web site at www.sec.gov shortly.

NovaMed develops, manufactures and markets breast implant products worldwide. The company's flagship product is the NovaGold(TM) alternative fill breast implant that utilizes a PVP hydrogel filling material which offers certain beneficial design characteristics not presently available with other fill materials. The company has also developed a line of saline filled products (NovaSaline(TM)), which are expected, subject to compliance with Food and Drug Administration clearance procedures, to be introduced into the U.S. market before the end of this year. The company currently manufactures and markets its products from facilities in Minneapolis, Minnesota and Monheim, Germany.

This release contains forward-looking statements that are made pursuant to the safe harbor provisions of the Securities Litigation Reform Act of 1995. Forward-looking statements involve the known and unknown risks and uncertainties that may cause the company's actual results in future periods to differ materially from that which is anticipated.